Together with previous published cases [56], our findings support the classification of CNS-JXG neoplasms with BRAF V600E into the current “L group” histiocytic neoplasm category [21], with all CNS-JXG neoplasms benefiting from upfront molecular testing including MAPK/ERK pathway mutations and possibly also ALK fusions/mutations [12]. This evidence concerns the gene BRAF and histiocytic neoplasm.